Pernix Therapeutics Holdings has obtained approval from the US Food and Drug Administration (FDA) for its Treximet (sumatriptan and naproxen sodium) for use in paediatric patients aged 12 years and older to treat migraine with or without aura.

Treximet has been formulated with Pozens’s patented technology of combining a triptan with a non-steroidal anti-inflammatory drug (NSAID) and GlaxoSmithKline’s (GSK) RT technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In 2008, the company first received FDA approval for Trexime as an acute treatment of migraine in adults.

"This expanded indication exemplifies our strategy to expand the reach of our current product portfolio to address additional underserved therapeutic areas, thereby adding value for patients and shareholders alike."

Pernix chairman and CEO Doug Drysdale said: "We are pleased with FDA’s decision and look forward to bringing migraine relief to paediatric patients by making the new Treximet dose available in the third quarter of this year.

"This expanded indication exemplifies our strategy to expand the reach of our current product portfolio to address additional underserved therapeutic areas, thereby adding value for patients and shareholders alike."

See Also:

The latest approval was based on pivotal Phase III safety and efficacy clinical trial and long-term safety and pharmacokinetic data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Pernix, both demonstrated that Treximet is significantly effective than placebo in treating migraine in paediatric patients and has a favourable safety profile similar to that of Treximet for adults.

Pernix noted that the recommended dose for paediatric patients 12 years of age and older is a single tablet of Treximet 10mg/60mg (sumatriptan 10mg and naproxen sodium 60mg) per 24-hour period and the maximum recommended dose is 85mg/500mg per 24-hour period.